21:20:21 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-28 Bokslutskommuniké 2024
2024-11-22 Kvartalsrapport 2024-Q3
2024-08-30 Kvartalsrapport 2024-Q2
2024-05-24 Kvartalsrapport 2024-Q1
2024-05-10 Ordinarie utdelning XINT 0.00 SEK
2024-05-08 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-11-24 Kvartalsrapport 2023-Q3
2023-08-30 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-05-15 Ordinarie utdelning XINT 0.00 SEK
2023-05-12 Årsstämma 2023
2023-02-24 Bokslutskommuniké 2022
2022-11-28 Extra Bolagsstämma 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-20 Kvartalsrapport 2022-Q1
2022-05-09 Ordinarie utdelning XINT 0.00 SEK
2022-05-06 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-19 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-07-05 Extra Bolagsstämma 2021
2021-05-21 Kvartalsrapport 2021-Q1
2021-05-10 Ordinarie utdelning XINT 0.00 SEK
2021-05-07 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-06-10 Ordinarie utdelning XINT 0.00 SEK
2020-06-09 Årsstämma 2020
2020-05-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-29 Kvartalsrapport 2019-Q3
2019-08-30 Kvartalsrapport 2019-Q2
2019-05-28 Ordinarie utdelning XINT 0.00 SEK
2019-05-27 Årsstämma 2019
2019-05-23 Kvartalsrapport 2019-Q1
2019-02-27 Bokslutskommuniké 2018
2018-11-28 Kvartalsrapport 2018-Q3
2018-09-21 Extra Bolagsstämma 2018
2018-08-29 Kvartalsrapport 2018-Q2
2018-05-30 Ordinarie utdelning XINT 0.00 SEK
2018-05-29 Årsstämma 2018
2018-05-25 Kvartalsrapport 2018-Q1
2018-02-22 Bokslutskommuniké 2017
2017-11-23 Kvartalsrapport 2017-Q3
2017-08-30 Kvartalsrapport 2017-Q2
2017-05-19 Ordinarie utdelning XINT 0.00 SEK
2017-05-18 Årsstämma 2017
2017-05-18 Kvartalsrapport 2017-Q1
2017-02-28 Bokslutskommuniké 2016
2016-11-23 Kvartalsrapport 2016-Q3
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-31 Ordinarie utdelning XINT 0.00 SEK
2016-05-30 Årsstämma 2016
2016-04-26 Bokslutskommuniké 2015

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Xintela är verksamt inom bioteknik. Bolagets kompetens återfinns inom regenerativ medicin, samt behandling av cancer, ledbroskskador samt hjärntumörer. Forskningen baseras på utvecklandet av proteinmolekyler som har kapacitet att känna av förändringar på cellers yta, vilket möjliggör identifiering av de stamceller som är på väg att utvecklas till broskceller. Bolaget grundades under 2009 och har sitt huvudkontor i Lund.
2023-05-12 10:10:00

Today, Friday 12 May 2023, the Annual General Meeting was held in Xintela AB (publ). The following main decisions were made. The decisions were taken unanimously.

Profit allocation and decision on discharge from liability
The meeting decided, in accordance with the board's proposal, that no dividend is to be paid for the financial year 2022 and that the company's results shall be carried forward.

The meeting granted the board members and the CEO discharge from liability for the financial year 2022.

Election and remuneration of the board and auditor
The meeting decided that the board shall consist of five board members without deputies. Gregory Batcheller, Lars Hedbys, Maarten de Chateau, Hans-Joachim Simons and Thomas Eldered were re-elected as board members. Gregory Batcheller was re-elected chairman of the board.

The meeting further decided that remuneration to the members of the board shall amount to a total of SEK 900,000, whereby SEK 300,000 shall be paid to the chairman of the board and SEK 150,000 shall be paid to other board members.

The meeting also decided to re-elect Öhrlings PricewaterhouseCoopers AB as auditor and that the auditor's fee should be paid according to approved invoices.

Issue authorizations
The meeting decided, in accordance with the board's proposal, to authorize the board to, within the limits of the articles of association, only with preferential rights for the company's shareholders, decide on a new issue of shares or the issue of convertibles or warrants.

The meeting further decided, in accordance with the board's proposal, to authorize the board to, deviating from the shareholders' pre-emptive rights, decide on a new issue of shares or the issue of convertibles or warrants. Decisions supported by the authorization may not result in the number of shares in the company being increased by more than a total of 20 percent of the number of shares outstanding at the time of the meeting. The purpose of the authorization, and the reason for the deviation from the shareholders' preferential right, is to enable the company to widen the ownership circle, acquire or enable the acquisition of working capital, increase the liquidity of the share, carry out business acquisitions or acquire or enable the acquisition of capital for business acquisitions.

Introduction of incentive programs
The meeting decided in accordance with the board's proposal to introduce a long-term incentive program for senior executives, employees and consultants in Xintela AB (publ) by issuing warrants.

The meeting further decided, in accordance with Flerie Invest AB's proposal, to introduce a long-term incentive program for board members in Xintela AB (publ) by issuing warrants.